Irene Lurkin

The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.

Bas W.G. van Rhijn, Irene Lurkin, François Radvanyi et al. · PubMed · 2001 · 309 citations

Tumor Biology, Surgical Oncology, Urology +15

FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

Lucie C. Kompier, Irene Lurkin, Madelon N.M. van der Aa et al. · PLoS ONE · 2010 · 305 citations · Full text

Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome

Yves Allory, Willemien Beukers, Ana Sagrera et al. · European Urology · 2013 · 280 citations · Full text

Urology, Somatic Variant, Genitourinary Cancer +7

A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine

Johanna M.M. van Oers, Irene Lurkin, Antonius J.A. van Exsel et al. · Clinical Cancer Research · 2005 · 160 citations

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders

Bas W.G. van Rhijn, Angela A.G. van Tilborg, Irene Lurkin et al. · European Journal of Human Genetics · 2002 · 148 citations

Tumor Biology, Urology, Genitourinary Cancer +7